Aprea Therapeutics, Inc. (NASDAQ:APRE) Short Interest Update

Aprea Therapeutics, Inc. (NASDAQ:APRE) was the recipient of a large increase in short interest in the month of January. As of January 31st, there was short interest totalling 44,900 shares, an increase of 271.1% from the January 15th total of 12,100 shares. Currently, 0.9% of the shares of the company are sold short. Based on an average daily volume of 28,300 shares, the short-interest ratio is presently 1.6 days.

Institutional Trading of Aprea Therapeutics

An institutional investor recently bought a new position in Aprea Therapeutics stock. Dimensional Fund Advisors LP acquired a new stake in Aprea Therapeutics, Inc. (NASDAQ:APRE) during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 11,071 shares of the company’s stock, valued at approximately $45,000. Dimensional Fund Advisors LP owned about 0.20% of Aprea Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors own 34.19% of the company’s stock.

Analysts Set New Price Targets

Separately, HC Wainwright restated a “buy” rating and set a $20.00 price target on shares of Aprea Therapeutics in a research report on Wednesday, January 15th.

Aprea Therapeutics Trading Up 3.6 %

Aprea Therapeutics stock traded up $0.12 during midday trading on Wednesday, hitting $3.43. 8,490 shares of the stock were exchanged, compared to its average volume of 38,521. The stock’s 50-day simple moving average is $3.61 and its 200 day simple moving average is $3.44. Aprea Therapeutics has a fifty-two week low of $2.15 and a fifty-two week high of $8.85. The stock has a market capitalization of $18.62 million, a price-to-earnings ratio of -1.22 and a beta of 0.76.

Aprea Therapeutics Company Profile

Aprea Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors.